| Amanda Anne Reed, | |
|
3232 N Ballard Rd Ste 100, Appleton, WI 54911-8804 | |
| (920) 729-7105 | |
| Not Available |
| Full Name | Amanda Anne Reed |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 16 Years |
| Location | 3232 N Ballard Rd Ste 100, Appleton, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275707556 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 54172-20 (Wisconsin) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Womens Care Of Wisconsin Sc | 3072416601 | 21 |
News Archive
California Attorney General Xavier Becerra pledged Friday to redouble his efforts as the Affordable Care Act's leading defender, saying attacks by the Trump Administration threaten health care for millions of Americans.
A new study from the University of Helsinki presents the current state of knowledge on the exposure and vulnerability of Indigenous Peoples to environmental pollution, reviewing the innumerable impacts that pollution poses on Indigenous communities from all over the world.
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 862,500 shares of its common stock and warrants to purchase an additional 431,250 shares (15% of the shares and warrants sold in this offering), at a public offering price of $4.00 per share and $0.001 per warrant, respectively, in connection with its previously announced underwritten public offering of 5,750,000 shares of common stock, and warrants to purchase up to an aggregate of 2,875,000 shares of common stock, bringing the total gross proceeds from the offering to approximately $26,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by Advaxis, Inc.
Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the filing of a New Drug Submission (NDS) with Health Canada's Therapeutic Products Directorate (TPD) seeking Canadian approval of intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults with AF for up to 7 days.
› Verified 3 days ago
| Entity Name | Womens Care Of Wisconsin Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003811993 PECOS PAC ID: 3072416601 Enrollment ID: O20040130000061 |
News Archive
California Attorney General Xavier Becerra pledged Friday to redouble his efforts as the Affordable Care Act's leading defender, saying attacks by the Trump Administration threaten health care for millions of Americans.
A new study from the University of Helsinki presents the current state of knowledge on the exposure and vulnerability of Indigenous Peoples to environmental pollution, reviewing the innumerable impacts that pollution poses on Indigenous communities from all over the world.
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 862,500 shares of its common stock and warrants to purchase an additional 431,250 shares (15% of the shares and warrants sold in this offering), at a public offering price of $4.00 per share and $0.001 per warrant, respectively, in connection with its previously announced underwritten public offering of 5,750,000 shares of common stock, and warrants to purchase up to an aggregate of 2,875,000 shares of common stock, bringing the total gross proceeds from the offering to approximately $26,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by Advaxis, Inc.
Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the filing of a New Drug Submission (NDS) with Health Canada's Therapeutic Products Directorate (TPD) seeking Canadian approval of intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults with AF for up to 7 days.
› Verified 3 days ago
| Entity Name | Theda Clark Ob Hospitalists Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295510196 PECOS PAC ID: 9335592187 Enrollment ID: O20240127000748 |
News Archive
California Attorney General Xavier Becerra pledged Friday to redouble his efforts as the Affordable Care Act's leading defender, saying attacks by the Trump Administration threaten health care for millions of Americans.
A new study from the University of Helsinki presents the current state of knowledge on the exposure and vulnerability of Indigenous Peoples to environmental pollution, reviewing the innumerable impacts that pollution poses on Indigenous communities from all over the world.
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 862,500 shares of its common stock and warrants to purchase an additional 431,250 shares (15% of the shares and warrants sold in this offering), at a public offering price of $4.00 per share and $0.001 per warrant, respectively, in connection with its previously announced underwritten public offering of 5,750,000 shares of common stock, and warrants to purchase up to an aggregate of 2,875,000 shares of common stock, bringing the total gross proceeds from the offering to approximately $26,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by Advaxis, Inc.
Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the filing of a New Drug Submission (NDS) with Health Canada's Therapeutic Products Directorate (TPD) seeking Canadian approval of intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults with AF for up to 7 days.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amanda Anne Reed, 3232 N Ballard Rd Ste 100, Appleton, WI 54911-8804 Ph: (920) 729-7105 | Amanda Anne Reed, 3232 N Ballard Rd Ste 100, Appleton, WI 54911-8804 Ph: (920) 729-7105 |
News Archive
California Attorney General Xavier Becerra pledged Friday to redouble his efforts as the Affordable Care Act's leading defender, saying attacks by the Trump Administration threaten health care for millions of Americans.
A new study from the University of Helsinki presents the current state of knowledge on the exposure and vulnerability of Indigenous Peoples to environmental pollution, reviewing the innumerable impacts that pollution poses on Indigenous communities from all over the world.
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 862,500 shares of its common stock and warrants to purchase an additional 431,250 shares (15% of the shares and warrants sold in this offering), at a public offering price of $4.00 per share and $0.001 per warrant, respectively, in connection with its previously announced underwritten public offering of 5,750,000 shares of common stock, and warrants to purchase up to an aggregate of 2,875,000 shares of common stock, bringing the total gross proceeds from the offering to approximately $26,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by Advaxis, Inc.
Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the filing of a New Drug Submission (NDS) with Health Canada's Therapeutic Products Directorate (TPD) seeking Canadian approval of intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults with AF for up to 7 days.
› Verified 3 days ago
Christopher W Wagener, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1531 S Madison St, Appleton, WI 54915 Phone: 920-730-4413 | |
Mark W Faustich, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1531 S Madison St, Appleton, WI 54915 Phone: 920-730-4413 | |
Suzanne Swanson, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: W5282 Amy Ave, Appleton, WI 54915 Phone: 920-358-1900 Fax: 920-358-1909 | |
C Danae Steele, Obstetrics & Gynecology Medicare: May Accept Medicare Assignments Practice Location: 1818 N Meade St, Appleton, WI 54911 Phone: 920-749-4000 Fax: 920-882-6372 | |
Deeann D B Reece, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1501 S Madison St, Appleton, WI 54915 Phone: 920-730-4435 | |
Dr. Jeffery J Cherney, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1818 N Meade St, Appleton, WI 54911 Phone: 920-749-4000 Fax: 920-749-4015 |